Head to Head Review: Enanta Pharmaceuticals (ENTA) vs. Biohaven Pharmaceutical (BHVN)

Enanta Pharmaceuticals (NASDAQ: ENTA) and Biohaven Pharmaceutical (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares Enanta Pharmaceuticals and Biohaven Pharmaceutical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enanta Pharmaceuticals $102.81 million 10.83 $17.71 million $0.88 66.13
Biohaven Pharmaceutical N/A N/A -$63.67 million ($5.22) -5.74

Enanta Pharmaceuticals has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Enanta Pharmaceuticals and Biohaven Pharmaceutical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals 0 2 2 0 2.50
Biohaven Pharmaceutical 0 0 6 0 3.00

Enanta Pharmaceuticals currently has a consensus target price of $45.25, indicating a potential downside of 22.24%. Biohaven Pharmaceutical has a consensus target price of $38.00, indicating a potential upside of 26.84%. Given Biohaven Pharmaceutical’s stronger consensus rating and higher possible upside, analysts clearly believe Biohaven Pharmaceutical is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares Enanta Pharmaceuticals and Biohaven Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals 17.23% 6.46% 6.11%
Biohaven Pharmaceutical N/A N/A N/A

Insider and Institutional Ownership

66.8% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of Biohaven Pharmaceutical shares are held by institutional investors. 9.3% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enanta Pharmaceuticals beats Biohaven Pharmaceutical on 9 of the 12 factors compared between the two stocks.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply